Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hepatocholangiocarcinoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Testing effectiveness (Phase 2)Looking for participantsNCT07105748
What this trial is testing

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Who this might be right for
Mixed Hepatocellular-cholangiocarcinoma
Fudan University 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT05211323
What this trial is testing

Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Who this might be right for
Combined Hepatocellular Carcinoma and CholangiocarcinomaStage III Liver CancerStage IV Liver Cancer
National Cancer Institute (NCI) 88
Not applicableActive Not RecruitingNCT05064553
What this trial is testing

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Who this might be right for
Hepatocellular CarcinomaHepatocellular CancerHepatitis B+2 more
Exact Sciences Corporation 2,990
Not applicableLooking for participantsNCT06849180
What this trial is testing

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Who this might be right for
Combined Hepatocellular-cholangiocarcinomaCombined Hepatocellular Carcinoma and CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Zhongda Hospital 198
Not applicableLooking for participantsNCT06541652
What this trial is testing

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Who this might be right for
HepatocholangiocarcinomaFibrolamellar CarcinomaHepatic Epithelioid Hemangioendothelioma+7 more
Federation Francophone de Cancerologie Digestive 150
Not applicableStudy completedNCT02730611
What this trial is testing

Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma

Who this might be right for
Morbid ObesityVertical Sleeve GastrectomyMetabolic Syndrome+3 more
Assistance Publique - Hôpitaux de Paris 124
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06855225
What this trial is testing

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Who this might be right for
Combined Hepatocellular and Cholangiocarcinoma
Mehmet Akce 29
Not applicableStudy completedNCT02762721
What this trial is testing

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Who this might be right for
Intrahepatic CholangiocarcinomaMixed Hepatocellular CholangiocarcinomaCholangiocarcinoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 131